![]() ![]() This chronic symptom burden (eg, sleep disturbance, inflammation, fatigue, and emotional distress) persists into survivorship and re-emerges over time, despite the best available pharmacological therapy. Patients with chronic hematological cancers experience ongoing disease-induced symptoms that are frequently not resolved by medical therapy and chronic maintenance therapy-associated toxicities. ![]() Approximately 60% of chronic hematological cancers, which include chronic leukemias (chronic lymphocytic and chronic myelogenous leukemia), low-grade lymphomas (follicular lymphomas), myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms (MPNs), are incurable and typically follow unpredictable remitting-relapsing pathways associated with varying needs for treatment, which may be distressing for patients thus, these patients have distinct needs from those of patients with solid tumors (eg, breast cancer). New noncurative therapies have led to improved survival for many hematological cancers however, these maintenance medicines leave patients in a state of chronic disease. Hematological cancers, a group of cancer subtypes that include blood- and lymph-related disorders, account for 11% of all cancer diagnoses in the United States, with an estimated 1.9 million patients with hematological cancer currently living in the United States. Symptom Burden and Sleep Disturbance Among Patients With Chronic Hematological Cancer ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |